<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB12036</drugbank-id>
  <name>Naquotinib</name>
  <description>Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.</description>
  <cas-number>1448232-80-1</cas-number>
  <unii>47DD4548PB</unii>
  <average-mass>562.719</average-mass>
  <monoisotopic-mass>562.337987244</monoisotopic-mass>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.</description>
    <direct-parent>Phenylpiperidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Piperidines</class>
    <subclass>Phenylpiperidines</subclass>
    <alternative-parent>2-heteroaryl carboxamides</alternative-parent>
    <alternative-parent>Acrylic acids and derivatives</alternative-parent>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aminopiperidines</alternative-parent>
    <alternative-parent>Aminopyrazines</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-acylpyrrolidines</alternative-parent>
    <alternative-parent>N-methylpiperazines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Pyrazinecarboxamides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>1,4-diazinane</substituent>
    <substituent>2-heteroaryl carboxamide</substituent>
    <substituent>4-aminopiperidine</substituent>
    <substituent>Acrylic acid or derivatives</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminopyrazine</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Ether</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acylpyrrolidine</substituent>
    <substituent>N-alkylpiperazine</substituent>
    <substituent>N-methylpiperazine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Phenylpiperidine</substituent>
    <substituent>Piperazine</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Pyrazine</substituent>
    <substituent>Pyrazine carboxylic acid or derivatives</substituent>
    <substituent>Pyrazinecarboxamide</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary aliphatic/aromatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002126</drugbank-id>
      <name>Naquotinib Mesylate</name>
      <unii>12T09LV21O</unii>
      <cas-number>1448237-05-5</cas-number>
      <inchikey>ALDUQYYVQWGTMR-GJFSDDNBSA-N</inchikey>
      <average-mass>658.82</average-mass>
      <monoisotopic-mass>658.326102407</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Protein Kinase Inhibitors</category>
      <mesh-id>D047428</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>5y9t</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Naquotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Naquotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Naquotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Naquotinib.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.18</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.88e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.31</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{[(3R)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{[(3R)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>562.719</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>562.337987244</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCC1=C(O[C@@H]2CCN(C2)C(=O)C=C)N=C(NC2=CC=C(C=C2)N2CCC(CC2)N2CCN(C)CC2)C(=N1)C(N)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C30H42N8O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QKDCLUARMDUUKN-XMMPIXPASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>120.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>160.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>63.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>71667668</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828348</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>44210447</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>170514</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>8RC</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3663929</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>